Medindia
Medindia LOGIN REGISTER
Advertisement

Robust Annual Growth in the Renal Cell Carcinoma Drug Market Will be Driven by the Uptake of GlaxoSmithKline's Votrient/Patorma and the Launches of Premium-Priced Emerging Therapies

Tuesday, June 29, 2010 General News
Advertisement
In 2009, Angiogenesis Inhibitors Captured More Than Three-Quarters of the Renal Cell Carcinoma Drug Market, According to Findings from Decision Resources

For more information, contact:

Decision Resources, Inc.

Christopher Comfort

781-296-2597

[email protected]

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close